molecular mechanisms underlying resistance and develop effective therapeutic strategies corresponding to each resistance mechanism.
This review focuses on the molecular mechanisms of acquired resistance to ALK-TKIs in ALK-rearranged NSCLC and discusses the potential therapeutic strategies for overcoming resistance.
| CHARACTERISTICS OF ALK

| Function of ALK in normal cells and cancer cells
ALK was first discovered as a fusion oncogene, NPM1-ALK in ALCL, which is an aggressive CD30 + T-cell lymphoma. 1 Mathew et al 7 mapped the mouse homolog of ALK to chromosome 17 and confirmed that human ALK was located on the short arm of chromosome 2. Anaplastic lymphoma kinase shows greatest sequence similarity to the insulin receptor subfamily of kinases and encodes a single-pass transmembrane receptor tyrosine kinase. Pleiotrophin, midkine, and heparin have been reported as potential ligands of ALK for inducing its activation. [8] [9] [10] However, as different results have been reported by other groups, the actual ligand remains to be identified. Finally, FAM150A and FAM150B were discovered by 2 different groups in 2015 and reported as genuine ligands of ALK. 11, 12 Expression of ALK protein in human adults has been shown only in a few cell types in the CNS and a few organs. Additionally, ALK has been shown to be expressed in the thalamus, hypothalamus, midbrain, and dorsal root ganglion in a mouse model during development. 13, 14 However, ALK knockout mice develop without obvious defects and have shown no differences in life spans and only mild behavioral phenotypes. 15, 16 Several types of ALK gene rearrangements (ALK fusion genes) have been found in many types of cancers. More than 10 years after the first identification of the ALK fusion gene, NPM-ALK, in ALCL, the EML4-ALK fusion oncogene was found in NSCLC. Until then, it had been believed that fusion oncogene-driven cancer was relatively rare in solid tumors. However, 3%-5% of NSCLC tumors have the ALK fusion gene. ALK rearrangement has been found in many types of cancer, and various fusion partners have been identified. The common characteristics of ALK fusion genes are that: (i) the ALK fusion protein is expressed constitutively through the active promoter of the fusion partner; and (ii) the fusion partner protein harbors the conserved oligomerization domain, such as the coiled-coil domain, which enables constitutive activation of ALK through dimerization or oligomerization. ALK-rearranged cancers are highly susceptible to aberrant growth signaling exerted from the constitutively activated ALK tyrosine kinase. Thus, inhibition exerted by the ALK-TKI markedly inhibits the tumor growth of ALK-rearranged cancer cells. In addition, transgenic mice expressing EML4-ALK in the lung under a surfactant protein C promoter, which is exclusively expressed in type II alveolar epithelial cells, developed hundreds of adenocarcinoma nodules in both lungs within a few weeks of birth. 17 An EML4-ALK lung cancer mouse model has also been easily generated by inhalation of adenoviruses of the Crispr-Cas9 system targeting the intron of EML4 and ALK.
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In NB, which is a secondary frequent childhood cancer, various point mutations in the ALK kinase domain have been identified. NSCLC in 2011, and crizotinib was also approved in Japan in 2012.
In the phase III clinical trials, the PFS was longer and ORR was higher for crizotinib than for chemotherapy. 26, 27 Crizotinib has been recommended as a first-line treatment of ALK-rearranged NSCLC.
Although crizotinib often shows marked tumor shrinkage in ALKrearranged NSCLC patients, crizotinib reportedly has limited potential against tumors metastasized to the brain because of poor penetration into the CSF. Indeed, disease progression has often been seen in the brain. One report showed that the crizotinib concentration in the CSF was 0.26% of that in the plasma. 28 A study using ABC transporter ABCB1 (abcb1a and abcb1b) knockout mice reported that the crizotinib concentration in the CSF was low, mainly because crizotinib was pumped out with ABCB1. 29 In addition, crizotinib is highly active against ROS1, which has a high degree of homology with ALK at the ATP binding site. The ROS1 fusion oncogene has been observed in approximately 1% of NSCLC cancer patients. 30 
| Alectinib
Alectinib was developed as a selective ALK inhibitor, and the IC 50 of ALK has been shown to be 2 nmol/L, which is lower than that of crizotinib. 31 In addition, alectinib has been shown to be active against several crizotinib-resistant mutations, such as L1196M or G1269A mutations, in ALK in vitro and in vivo xenograft models.
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A phase I/II clinical trial of alectinib against ALK-TKI treatmentna€ ıve ALK-rearranged NSCLC patients was carried out in Japan. The recommended dose of alectinib was determined to be 300 mg twice daily. The ORR was quite high (93.5%), and the PFS was reported to be over 3 years. 33 Another phase I/II clinical trial of alectinib for ALK-rearranged NSCLC patients who showed progression after crizotinib treatment was undertaken mainly in the USA.
The results showed that the recommended dose was 600 mg twice a day, which is double that decided on after the trial in Japan. Even in patients with crizotinib treatment history, an ORR of 52% and a PFS of 8.2 months were observed. 34 As alectinib is not a substrate of ABCB1 and undergoes relatively little pumping out through the blood brain barrier, high CSF penetration was reported. Accordingly, alectinib showed activity in brain metastases. 35 Two phase III clinical trials of alectinib compared with crizotinib in treatment-na€ ıve ALK-rearranged NSCLC patients were carried out in Japan (J-ALEX) and globally (ALEX). In these trials, the recommended dose of alectinib was 300 mg twice daily in J-ALEX, and 600 mg twice daily in ALEX. The PFS was longer for alectinib than for crizotinib (25.7 months for alectinib vs 10.4 months for crizotinib in J-ALEX, and 25.7 months for alectinib vs 11.1 months for crizotinib in ALEX).
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| Ceritinib
Ceritinib has a very low IC 50 of 150 pM to ALK in vitro; that is, 20-to 30-fold lower than that of crizotinib. Similar to alectinib, ceritinib is also active against several crizotinib-resistant mutations, such as L1196M and G1269A in ALK. 38, 39 Phase I clinical trials for ALK-rearranged NSCLC patients with and without prior crizotinib treatment showed an ORR of 58% and a PFS of 7.0 months. 40 It was reported that the response was seen even in CNS metastasis cases. 41 A phase III clinical trial comparing ceritinib with chemotherapy in advanced ALK-rearranged lung cancer with (ASCEND-5) or without prior crizotinib and chemotherapy (ASCEND-4) showed the superiority of ceritinib over chemotherapy.
The median PFS in the ASCEND-4 trial was 16.6 months for ceritinib vs 8.1 months for chemotherapy, and even in patients previously treated with both chemotherapy and crizotinib, the median PFS was 5.4 months for ceritinib and 1.6 months for chemotherapy. 42, 43 In addition, ceritinib treatment has been shown to be affected by low-fat meals: it was shown that a lower dose of 450 mg once a day with a low-fat meal gave similar exposure and a more favorable gastrointestinal safety profile than 750 mg once a day in the fasting state in ALK-rearranged NSCLC (ASCEND-8). 44 Moreover, ceritinib has been shown to be active against ROS1-rearranged NSCLC patients. 45 
| Brigatinib
Brigatinib was first reported as a selective ALK-TKI with a subnanomolar IC 50 against ALK in vitro and was also shown to be active against crizotinib-resistant L1196M gatekeeper mutation. 46 In the phase I/II clinical trial of brigatinib, 71 crizotinib refractory ALK-rearranged lung cancer patients were treated with brigatinib, and the ORR was 62% and the PFS was 13 months. Serious treatment-emergent adverse events were observed in some patients, and 6% of the patients died during treatment or within 31 days of the last dose of brigatinib. Thus, severe adverse events occurred, so the phase II recommended dose was set at 90 mg once daily and 180 mg once daily with a 7-day lead-in at 90 mg. 47 In the follow-up phase II study, the ORR was 45% in a group treated with 90 mg brigatinib once daily and 54% in patients treated with 180 mg once daily with a 7-day lead-in at 90 mg, and the PFS periods for the treatment groups were 9.2 and 12.9 months, respectively. Severe (grade ≥3) treatmentemergent adverse events were seen in 3% of the patients, and those pulmonary toxicities tended to be associated with older patients within shorter intervals (<7 days) between the last crizotinib and the first brigatinib. No such severe pulmonary adverse events were seen after dose escalation to 180 mg after a 7-day lead in at 90 mg. 48 Brigatinib has been shown to be active against almost all of the crizotinib-, alectinib-, or ceritinib-resistant mutations, including the G1202R mutation in ALK, which is highly resistant to crizotinib, alectinib, or ceritinib. However, from an analysis of a few brigatinibresistant cases, G1202R point mutations were also seen. 49 In 2017, brigatinib was approved in the USA for the treatment of ALK-rearranged NSCLC patients with crizotinib-refractory or -intolerable disease. Of note, it was reported that brigatinib has some activity against ROS1-rearranged cancer, and EGFR-C797S/T790M/activating mutation mediated osimertinib resistance by combining with anti-EGFR antibody. 
| ME CH ANISMS OF ALK-TKI RESISTAN CE
| Mutation or gene amplification of ALKmediated resistance
In patients with ALK-rearranged lung cancer, when crizotinib was used as the initial treatment of ALK-TKI, >60% of the patients experienced partial response or complete response, and the PFS of crizotinib was approximately 10 months, which suggests that recurrence due to acquired resistance occurs within 1 year in >50% of cases. In 2010, ALK-L1196M (the ALK-1196th amino acid leucine is converted to methionine) and C1156Y mutations were found in a patient refractory to crizotinib by analyzing the cells in pleural effusion; those ALK mutants conferred resistance to crizotinib. 56 Subsequently, various mutations, such as G1269A, I1151T-ins, G1202R, S1206Y, and I1171T, have been reported as crizotinib-resistant mutations in addition to the above two, and the L1196M gatekeeper mutation, which is in the equivalent position of the EGFR-TKI-resistant gatekeeper mutation EGFR-T790M, has been most frequently observed in crizotinib-resistant patients. 49, [57] [58] [59] However, the resistant mutation nisms. 60 Among these secondary mutations, the G1202R mutation is resistant to all three of these ALK inhibitors, but the F1174C/L/V ceritinib-resistant mutations are sensitive to alectinib; additionally, the I1171T/N/S and V1180L mutations, which confer alectinib resistance, are sensitive to ceritinib. 38, 49, 60 In contrast, brigatinib and lorlatinib have also been shown to be effective for various ALK-TKI-resistant mutations, including L1196M ( Figure 1A) . 46, 61 However, it has been shown that at least 2 mutations occur within the ALK kinase region, which makes them resistant. Regarding brigatinib, E1210K + S1206C, and E1210K + D1203N mutation has been found in patients with brigatinib resistance. 49 For lorlatinib, the C1156Y + L1198F mutation in ALK has been found to confer resistance in lorlatinib-resistant patients. Interestingly, an L1198F double mutation has also been shown to be resensitized to crizotinib as the phenylalanine substitution at L1198 does not clash with crizotinib and in fact moves slightly closer to the inhibitor ( Figures 1B and 2 ). 62 
| Bypass pathway or other mechanismmediated resistance
In the crizotinib-resistant cases in which the resistance mechanisms were examined, secondary resistance mutation or ALK fusion gene amplification was observed in only one-third of the cases. From the analysis of the remaining cases and the cell line models, it has been reported that amplification of the cKIT gene with increased expression of stem cell factor (SCF) as its ligand, activation of EGFR was found to be the mechanism of resistance to crizotinib (Figure 3 ). 57 The concomitant mutation of KRAS or EGFR has also been reported, but with low frequency. 59, 63 Activation of IGF1R has been found in crizotinib-resistant cases. Furthermore, in studies using cultured cell lines and cell lines derived from resistant patients, 64 it has been reported that resistance due to activation of Src is observed relatively frequently, but the detailed molecular mechanism underlying activation of Src is not yet clear. 65 As crizotinib is a potent inhibitor of cMET with an even lower IC 50 than that for ALK, and was originally developed as a cMET inhibitor, cMET overactivation, such as MET gene amplification-mediated resistance, has not been observed.
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A ceritinib-resistant mechanism other than secondary mutation is involved in an activating mutation of MEK (MAP2K1-K57N), and an MEK inhibitor with ALK-TKI has been found to overcome the resistance. Analysis of cell lines derived from ceritinib-resistant patients has shown that overexpression of p-glycoprotein ABCB1, which is one of the ABC transporters that transport hydrophobic substrates from cells or across the blood brain barrier to protect the brain, conferred resistance to ceritinib and crizotinib but not to alectinib or lorlatinib. Thus, the resistance can be overcome by alectinib or lorlatinib, which have not been shown to be substrates of p-glycoprotein, or by the combination of a p-glycoprotein inhibitor, such as MS209 69 or verapamil 70 with ceritinib. This p-glycoprotein overexpression was found in three out of 13 patients who had been treated with crizotinib or ceritinib. 71 Of note, ceritinib has been shown to actively inhibit IGF1R, so IGF1R activation-mediated resistance, found in crizotinib-refractory cases, might not be observed. 64 An alectinib-resistant mechanism other than secondary mutation has been shown in cMET activation through MET gene amplification or elevation of its ligand hepatocyte growth factor (HGF) from an analysis of patients' samples and cell line models. cMET activationmediated resistance would be able to be overcome by crizotinib.
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Basically, cMET overactivation can potentially confer resistance to any ALK-TKIs except for crizotinib ( Figure 3 ).
To overcome resistance-mediated bypass pathway activation, combination therapy to inhibit both ALK and the bypass pathways are considered to be necessary. However, no combination therapy has been clinically approved that overcomes bypass pathway- be the sole driver of the resistance. 49 In contrast, histological transformation from adenocarcinoma to SCLC has been reported in several ALK-TKI-refractory cases, such as alectinib-resistant cases.
Similar to the SCLC transformation, which is well-known in EGFR-TKI-resistant cases, classic cytotoxic chemotherapy is thought to be effective for overcoming resistance. • Elucidation of unidentified resistance mechanisms in approximately 25% of resistant cases. • Resistance mechanisms and fusion variants (are G1202R mutations only seen in EML4-ALK-variant 3 patients?).
• Sensitive detection methods to identify the resistance mechanisms from blood (and tissues).
• Heterogeneity and dominance of the populations with resistant tumors.
• Drugs to overcome compound-resistant mutations to lorlatinib.
• Up-front combination therapy to effectively eradicate persistent cancer cells.
• Understanding the immune checkpoint in ALK-rearranged lung cancer.
In addition, it is also important to fully understand the mecha- 
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